Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 17/2010

01-12-2010 | Review Article

Pharmacological Management of Essential Tremor

Authors: Reza Sadeghi, William G. Ondo, MD

Published in: Drugs | Issue 17/2010

Login to get access

Abstract

Essential tremor (ET) is a common movement disorder with clinical features that manifest with both motor (tremor and balance disorders) and non-motor (such as mild cognitive deficits and hearing loss) symptoms. The diagnosis of ET is based on the presence of an action tremor of greater severity than enhanced physiological tremor, without other identifiable causes. Patients with ET experience a decrease in the performance of their motor skills and social activities, and a decline in their quality of life. The pathophysiology of ET is still not clear. Pharmacotherapy for ET is indicated if the disease interferes with the patient’s quality of life. Propranolol, a nonselective β-adrenergic receptor antagonist, and primidone, an antiepileptic, remain the standard treatments for ET. However, studies show that several other agents, including topiramate, gabapentin and zonisamide, might also be beneficial. Local injections of botulinum toxins and surgical interventions such as thalamic deep brain stimulation play a role as alternative options when pharmacological treatment is not satisfactory. Several new agents including 1-octanol, pregabalin and sodium oxybate are currently under investigation.
Literature
1.
Benito-Leon J, Bermejo-Pareja F, Morales JM, et al. Prevalence of essential tremor in three elderly populations of central Spain. Mov Disord 2003 Apr; 18(4): 389–94PubMedCrossRef
2.
Wenning GK, Kiechl S, Seppi K, et al. Prevalence of movement disorders in men and women aged 50–89 years (Bruneck Study cohort): a population-based study. Lancet Neurol 2005 Dec; 4(12): 815–20PubMedCrossRef
3.
4.
Louis ED, Ottman R, Hauser WA. How common is the most common adult movement disorder? Estimates of the prevalence of essential tremor throughout the world. Mov Disord 1998 Jan; 13(1): 5–10PubMedCrossRef
5.
Deuschl G, Bain P, Brin M. Consensus statement of the Movement Disorder Society on Tremor: Ad Hoc Scientific Committee. Mov Disord 1998; 13 Suppl. 3: 2–23PubMedCrossRef
6.
Lou JS, Jankovic J. Essential tremor: clinical correlates in 350 patients. Neurology 1991 Feb; 41 (2 Pt 1): 234–8PubMedCrossRef
7.
Jankovic J. Essential tremor: clinical characteristics. Neurology 2000; 54 (11 Suppl. 4): S21–5PubMed
8.
Ondo WG, Sutton L, Dat Vuong K, et al. Hearing impairment in essential tremor. Neurology 2003 Oct 28; 61(8): 1093–7PubMedCrossRef
9.
Ondo WG, Lai D. Association between restless legs syndrome and essential tremor. Mov Disord 2006 Apr; 21(4): 515–8PubMedCrossRef
10.
Gasparini M, Bonifati V, Fabrizio E, et al. Frontal lobe dysfunction in essential tremor: a preliminary study. J Neurol 2001 May; 248(5): 399–402PubMedCrossRef
11.
Duane DD, Vermilion KJ. Cognitive deficits in patients with essential tremor [letter]. Neurology 2002 Jun 11; 58(11): 1706; author reply 1706PubMedCrossRef
12.
Lombardi WJ, Woolston DJ, Roberts JW, et al. Cognitive deficits in patients with essential tremor. Neurology 2001 Sep 11; 57(5): 785–90PubMedCrossRef
13.
Lacritz LH, Dewey Jr R, Giller C, et al. Cognitive functioning in individuals with “benign” essential tremor. J Int Neuropsychol Soc 2002 Jan; 8(1): 125–9PubMedCrossRef
14.
15.
Putzke JD, Whaley NR, Baba Y, et al. Essential tremor: predictors of disease progression in a clinical cohort. J Neurol Neurosurg Psychiatry 2006 Nov; 77(11): 1235–7PubMed
16.
Louis ED, Thawani SP, Andrews HF. Prevalence of essential tremor in a multiethnic, community-based study in northern Manhattan, New York, N.Y. Neuroepidemiology 2009; 32(3): 208–14PubMedCrossRef
17.
Deuschl G, Bergman H. Pathophysiology of non-parkinsonian tremors. Mov Disord 2002; 17 Suppl. 3: S41–8PubMedCrossRef
18.
Duncan R, Bone I, Melville ID. Essential tremor cured by infarction adjacent to the thalamus. J Neurol Neurosurg Psychiatry 1988 Apr; 51(4): 591–2PubMedCrossRef
19.
Dupuis MJ, Delwaide PJ, Boucquey D, et al. Homolateral disappearance of essential tremor after cerebellar stroke. Mov Disord 1989; 4(2): 183–7PubMedCrossRef
20.
Nagaratnam N, Kalasabail G. Contralateral abolition of essential tremor following a pontine stroke. J Neurol Sci 1997 Aug; 149(2): 195–6PubMedCrossRef
21.
Hallett M, Dubinsky RM. Glucose metabolism in the brain of patients with essential tremor. J Neurol Sci 1993 Jan; 114(1): 45–8PubMedCrossRef
22.
23.
Louis ED, Vonsattel JP, Honig LS, et al. Neuropathologic findings in essential tremor. Neurology 2006 Jun 13; 66(11): 1756–9PubMedCrossRef
24.
Louis ED. Essential tremor: evolving clinicopathological concepts in an era of intensive post-mortem enquiry. Lancet Neurol 2010 Jun; 9(6): 613–22PubMedCrossRef
25.
Nasrallah HA, Schroeder D, Petty F. Alcoholism secondary to essential tremor. J Clin Psychiatry 1982 Apr; 43(4): 163–4PubMed
26.
Koller WC, Biary N. Effect of alcohol on tremors: comparison with propranolol. Neurology 1984 Feb; 34(2): 221–2PubMedCrossRef
27.
Klebe S, Stolze H, Grensing K, et al. Influence of alcohol on gait in patients with essential tremor. Neurology 2005 Jul 12; 65(1): 96–101PubMedCrossRef
28.
Martinez C, Garcia-Martin E, Alonso-Navarro H, et al. Alcohol dehydrogenase 2 genotype and allelic variants are not associated with the risk for essential tremor. Clin Neuropharmacol 2007 Jul–Aug; 30(4): 196–200PubMed
29.
Schroeder D, Nasrallah HA. High alcoholism rate in patients with essential tremor. Am J Psychiatry 1982 Nov; 139(11): 1471–3PubMed
30.
Rautakorpi I, Marttila RJ, Rinne UK. Alcohol consumption of patients with essential tremor. Acta Neurol Scand 1983 Sep; 68(3): 177–9PubMedCrossRef
31.
FDA. Food additive safety profile: 1-octanol. Silver Spring (MD): US FDA, 1998
32.
Sinton CM, Krosser BI, Walton KD, et al. The effectiveness of different isomers of octanol as blockers of harmaline-induced tremor. Pflugers Arch 1989 May; 414(1): 31–6PubMedCrossRef
33.
Bushara KO, Goldstein SR, Grimes Jr GJ, et al. Pilot trial of 1-octanol in essential tremor. Neurology 2004 Jan 13; 62(1): 122–4PubMedCrossRef
34.
Shill HA, Bushara KO, Mari Z, et al. Open-label dose-escalation study of oral 1-octanol in patients with essential tremor. Neurology 2004 Jun 22; 62(12): 2320–2PubMedCrossRef
35.
Zesiewicz TA, Elble R, Louis ED, et al. Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2005 Jun 28; 64(12): 2008–20PubMedCrossRef
36.
Tolosa ES, Loewenson RB. Essential tremor: treatment with propranolol. Neurology 1975 Nov; 25(11): 1041–4PubMedCrossRef
37.
Abila B, Wilson JF, Marshall RW, et al. The tremorolytic action of beta-adrenoceptor blockers in essential, physiological and isoprenaline-induced tremor is mediated by beta-adrenoceptors located in a deep peripheral compartment. Br J Clin Pharmacol 1985 Oct; 20(4): 369–76PubMedCrossRef
38.
Cleeves L, Findley LJ. Propranolol and propranolol-LA in essential tremor: a double blind comparative study. J Neurol Neurosurg Psychiatry 1988 Mar; 51(3): 379–84PubMedCrossRef
39.
Calzetti S, Findley LJ, Gresty MA, et al. Metoprolol and propranolol in essential tremor: a double-blind, controlled study. J Neurol Neurosurg Psychiatry 1981 Sep; 44(9): 814–9PubMedCrossRef
40.
Koller WC, Biary N. Metoprolol compared with propranolol in the treatment of essential tremor. Arch Neurol 1984 Feb; 41(2): 171–2PubMedCrossRef
41.
Teravainen H, Larsen A, Fogelholm R. Comparison between the effects of pindolol and propranolol on essential tremor. Neurology 1977 May; 27(5): 439–42PubMedCrossRef
42.
Lee KS, Kim JS, Kim JW, et al. A multicenter randomized crossover multiple-dose comparison study of arotinolol and propranolol in essential tremor. Parkinsonism Relat Disord 2003 Aug; 9(6): 341–7PubMedCrossRef
43.
Nagaki S, Ratnaraj N, Patsalos PN. Blood and cerebrospinal fluid pharmacokinetics of primidone and its primary pharmacologically active metabolites, phenobarbital and phenylethylmalonamide in the rat. Eur J Drug Metab Pharmacokinet 1999 Jul–Sep; 24(3): 255–64PubMedCrossRef
44.
Martines C, Gatti G, Sasso E, et al. The disposition of primidone in elderly patients. Br J Clin Pharmacol 1990 Oct; 30(4): 607–11PubMedCrossRef
45.
46.
47.
O’Suilleabhain P, Dewey Jr RB. Randomized trial comparing primidone initiation schedules for treating essential tremor. Mov Disord 2002 Mar; 17(2): 382–6PubMedCrossRef
48.
Koller WC, Vetere-Overfield B. Acute and chronic effects of propranolol and primidone in essential tremor. Neurology 1989 Dec; 39(12): 1587–8PubMedCrossRef
49.
Galvez-Jimenez N, Hargreave M. Topiramate and essential tremor. Ann Neurol 2000 Jun; 47(6): 837–8PubMedCrossRef
50.
Connor GS. A double-blind placebo-controlled trial of topiramate treatment for essential tremor. Neurology 2002 Jul 9; 59(1): 132–4PubMedCrossRef
51.
Ondo WG, Jankovic J, Connor GS, et al. Topiramate in essential tremor: a double-blind, placebo-controlled trial. Neurology 2006 Mar 14; 66(5): 672–7PubMedCrossRef
52.
Gironell A, Kulisevsky J, Barbanoj M, et al. A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor. Arch Neurol 1999 Apr; 56(4): 475–80PubMedCrossRef
53.
Ondo W, Hunter C, Vuong KD, et al. Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. Mov Disord 2000 Jul; 15(4): 678–82PubMedCrossRef
54.
Pahwa R, Lyons K, Hubble JP, et al. Double-blind controlled trial of gabapentin in essential tremor. Mov Disord 1998 May; 13(3): 465–7PubMedCrossRef
55.
Bushara KO, Malik T, Exconde RE. The effect of levetiracetam on essential tremor. Neurology 2005 Mar 22; 64(6): 1078–80PubMedCrossRef
56.
Elble RJ, Lyons KE, Pahwa R. Levetiracetam is not effective for essential tremor. Clin Neuropharmacol 2007 Nov–Dec; 30(6): 350–6PubMedCrossRef
57.
Sanz-Cartagena P, Fossas P, Floriach-Robert M, et al. Effectiveness and safety of levetiracetam in patients with essential tremor: data from an open 11-week follow-up trial. Rev Neurol 2007 Aug 1–15; 45(3): 134–6PubMed
58.
Ondo WG, Jimenez JE, Vuong KD, et al. An open-label pilot study of levetiracetam for essential tremor. Clin Neuropharmacol 2004 Nov–Dec; 27(6): 274–7PubMedCrossRef
59.
Baruzzi A, Procaccianti G, Martinelli P, et al. Phenobarbital and propranolol in essential tremor: a double-blind controlled clinical trial. Neurology 1983 Mar; 33(3): 296–300PubMedCrossRef
60.
Sasso E, Perucca E, Calzetti S. Double-blind comparison of primidone and phenobarbital in essential tremor. Neurology 1988 May; 38(5): 808–10PubMedCrossRef
61.
Ferrara JM, Kenney C, Davidson AL, et al. Efficacy and tolerability of pregabalin in essential tremor: a randomized, double-blind, placebo-controlled, crossover trial. J Neurol Sci 2009 Oct 15; 285(1–2): 195–7PubMedCrossRef
62.
Zesiewicz TA, Ward CL, Hauser RA, et al. Pregabalin (Lyrica) in the treatment of essential tremor. Mov Disord 2007 Jan; 22(1): 139–41PubMedCrossRef
63.
Zesiewicz TA, Ward CL, Hauser RA, et al. A pilot, double-blind, placebo-controlled trial of pregabalin (Lyrica) in the treatment of essential tremor. Mov Disord 2007 Aug 15; 22(11): 1660–3PubMedCrossRef
64.
Zesiewicz TA, Ward CL, Hauser RA, et al. A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor. Mov Disord 2007 Jan 15; 22(2): 279–82PubMedCrossRef
65.
Handforth A, Martin FC, Kang GA, et al. Zonisamide for essential tremor: an evaluator-blinded study. Mov Disord 2009 Feb 15; 24(3): 437–40PubMedCrossRef
66.
Bermejo PE, Ruiz-Huete C, Dorado R, et al. Zonisamide in refractory essential tremor. Rev Neurol 2008 Feb 1–15; 46(3): 139–42PubMed
67.
68.
Morita S, Miwa H, Kondo T. Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol. Parkinsonism Relat Disord 2005 Mar; 11(2): 101–3PubMedCrossRef
69.
Raj V, Landess JS, Martin PR. Oxcarbazepine use in essential tremor. Ann Pharmacother 2006 Oct; 40(10): 1876–9PubMedCrossRef
70.
Biary N, al Deeb SM, Bahou Y. Long-term therapy of essential tremor with flunarizine. Eur Neurol 1995; 35(4): 217–9PubMedCrossRef
71.
Biary N, al Deeb SM, Langenberg P. The effect of flunarizine on essential tremor. Neurology 1991 Feb; 41 (2 Pt 1): 311–2PubMedCrossRef
72.
Vecchio I, Rampello L, Tornali C, et al. Flunarizine and essential tremor in the elderly. Arch Gerontol Geriatr 1996; 22 Suppl. 1: 73–7PubMedCrossRef
73.
74.
Biary N, Bahou Y, Sofi MA, et al. The effect of nimodipine on essential tremor. Neurology 1995 Aug; 45(8): 1523–5PubMedCrossRef
75.
Garcia Ruiz PJ, Garcia de Yebenes Prous J, Jimenez Jimenez J. Effect of nicardipine on essential tremor: brief report. Clin Neuropharmacol 1993 Oct; 16(5): 456–9PubMedCrossRef
76.
Topaktas S, Onur R, Dalkara T. Calcium channel blockers and essential tremor. Eur Neurol 1987; 27(2): 114–9PubMedCrossRef
77.
Brin MF, Lyons KE, Doucette J, et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology 2001 Jun 12; 56(11): 1523–8PubMedCrossRef
78.
Pahwa R, Busenbark K, Swanson-Hyland EF, et al. Botulinum toxin treatment of essential head tremor. Neurology 1995 Apr; 45(4): 822–4PubMedCrossRef
79.
Hertegard S, Granqvist S, Lindestad PA. Botulinum toxin injections for essential voice tremor. Ann Otol Rhinol Laryngol 2000 Feb; 109(2): 204–9PubMed
80.
Cho JW, Chu K, Jeon BS. Case of essential palatal tremor: atypical features and remarkable benefit from botulinum toxin injection. Mov Disord 2001 Jul; 16(4): 779–82PubMedCrossRef
81.
Gunal DI, Afsar N, Bekiroglu N, et al. New alternative agents in essential tremor therapy: double-blind placebo-controlled study of alprazolam and acetazolamide. Neurol Sci 2000 Oct; 21(5): 315–7PubMedCrossRef
82.
Huber SJ, Paulson GW. Efficacy of alprazolam for essential tremor. Neurology 1988 Feb; 38(2): 241–3PubMedCrossRef
83.
Biary N, Koller W. Kinetic predominant essential tremor: successful treatment with clonazepam. Neurology 1987 Mar; 37(3): 471–4PubMedCrossRef
84.
Thompson C, Lang A, Parkes JD, et al. A double-blind trial of clonazepam in benign essential tremor. Clin Neuropharmacol 1984; 7(1): 83–8PubMedCrossRef
85.
Uccellini D, Grampa G, La Spina I, et al. Mirtazapine in the treatment of essential tremor: an open-label, observer-blind study. Neuropsychiatr Dis Treat 2006 Mar; 2(1): 95–100PubMed
86.
Pahwa R, Lyons KE. Mirtazapine in essential tremor: a double-blind, placebo-controlled pilot study. Mov Disord 2003 May; 18(5): 584–7PubMedCrossRef
87.
Caccia MR, Osio M, Galimberti V, et al. Propranolol, clonidine, urapidil and trazodone infusion in essential tremor: a double-blind crossover trial. Acta Neurol Scand 1989 May; 79(5): 379–83PubMedCrossRef
88.
Ceravolo R, Salvetti S, Piccini P, et al. Acute and chronic effects of clozapine in essential tremor. Mov Disord 1999 May; 14(3): 468–72PubMedCrossRef
89.
Micheli F, Cersosimo MG, Raina G, et al. Quetiapine and essential tremor. Clin Neuropharmacol 2002 Nov–Dec; 25(6): 303–6PubMedCrossRef
90.
Serrano Duenas M. Acute pharmacological test of clonidine in essential tremor. Neurologia 1997 Jan; 12(1): 9–11PubMed
91.
Serrano-Duenas M. Clonidine versus propranolol in the treatment of essential tremor: a double-blind trial with a one-year follow-up. Neurologia 2003 Jun; 18(5): 248–54PubMed
92.
Koller W, Herbster G, Cone S. Clonidine in the treatment of essential tremor. Mov Disord 1986; 1(4): 235–7PubMedCrossRef
93.
Caccia MR, Mangoni A. Clonidine in essential tremor: preliminary observations from an open trial. J Neurol 1985; 232(1): 55–7PubMedCrossRef
94.
95.
96.
Obeso JA, Luquin MR, Artieda J, et al. Amantadine may be useful in essential tremor. Ann Neurol 1986 Jan; 19(1): 99–100PubMedCrossRef
97.
Gironell A, Kulisevsky J, Pascual-Sedano B, et al. Effect of amantadine in essential tremor: a randomized, placebo-controlled trial. Mov Disord 2006 Apr; 21(4): 441–5PubMedCrossRef
98.
Melmed C, Moros D, Rutman H. Treatment of essential tremor with the barbiturate T2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric acid). Mov Disord 2007 Apr 15; 22(5): 723–7PubMedCrossRef
99.
Frucht SJ, Houghton WC, Bordelon Y, et al. A single-blind, open-label trial of sodium oxybate for myoclonus and essential tremor. Neurology 2005 Dec 27; 65(12): 1967–9PubMedCrossRef
100.
Hallett M, Ravits J, Dubinsky RM, et al. A double-blind trial of isoniazid for essential tremor and other action tremors. Mov Disord 1991; 6(3): 253–6PubMedCrossRef
101.
Muenter MD, Daube JR, Caviness JN, et al. Treatment of essential tremor with methazolamide. Mayo Clin Proc 1991 Oct; 66(10): 991–7PubMedCrossRef
102.
Busenbark K, Pahwa R, Hubble J, et al. Double-blind controlled study of methazolamide in the treatment of essential tremor. Neurology 1993 May; 43(5): 1045–7PubMedCrossRef
103.
Busenbark K, Ramig L, Dromey C, et al. Methazolamide for essential voice tremor. Neurology 1996 Nov; 47(5): 1331–2PubMedCrossRef
104.
Ondo W, Jankovic J, Schwartz K, et al. Unilateral thalamic deep brain stimulation for refractory essential tremor and Parkinson’s disease tremor. Neurology 1998 Oct; 51(4): 1063–9PubMedCrossRef
Metadata
Title
Pharmacological Management of Essential Tremor
Authors
Reza Sadeghi
William G. Ondo, MD
Publication date
01-12-2010
Publisher
Springer International Publishing
Published in
Drugs / Issue 17/2010
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/11538180-000000000-00000

Other articles of this Issue 17/2010

Drugs 17/2010 Go to the issue

Adis Drug Profile

Trastuzumab

Leading Article

Drugs in Development for Tuberculosis

Review Article

Influence of Intensive versus Conventional Glucose Control on Microvascular and Macrovascular Complications in Type 1 and 2 Diabetes Mellitus

Adis Drug Evaluation

Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (Atripla®)

Review Article

Triple-Negative Breast Cancer

Adis Drug Evaluation

Olanzapine Long-Acting Injection